Valneva: positive opinion for Covid vaccine in Europe

(CercleFinance.com) - Valneva has announced that the CHMP of the European Medicines Agency has recommended a marketing authorisation (MA) in Europe for its Covid-19 vaccine candidate as a primary immunisation in adults aged 18 to 55 years.


The European Commission will review this recommendation and a decision is expected shortly. If granted, VLA2001 would be the first Covid-19 vaccine to receive standard marketing authorisation in Europe.

According to the vaccine company, the CHMP concluded by consensus after a thorough evaluation that the data on the vaccine are robust and meet the EU criteria of efficacy, safety and quality.

The speculative Valneva stock has increased by over 60% to around 12 euros over the past five trading days - from a "pre-Covid" price of a mere 2.5 euros.



Copyright (c) 2022 CercleFinance.com. All rights reserved.